Literature DB >> 23910028

Maternal immunization: an update for pediatricians.

Flor M Munoz1.   

Abstract

The immunization of women during pregnancy can protect both the mother and her infant against serious infectious diseases. The prevention of infection through maternal immunization reduces the risk of exposure to the baby, results in higher concentrations of transplacentally transferred pathogen-specific maternal antibodies to the newborn, and provides protection to the infant during a period of vulnerability. The benefits of vaccinating pregnant women outweigh any theoretic risk when there is a risk of exposure to an infectious disease that threatens the mother or the newborn's health. Toxoids and inactivated virus or bacterial vaccines are safe and cause no harm to the mother or fetus. Live vaccines, viral or bacterial, are contraindicated during pregnancy as a precaution because of the theoretic risk of infection of the fetus. However, there has been no evidence to date of direct fetal injury after the administration of live viral vaccines to pregnant women. The administration of immune globulin preparations to pregnant women results in no known risks to the fetus. In the United States, vaccines recommended in pregnancy include the seasonal influenza vaccine, tetanus toxoid, and the pertussis vaccine as a combined tetanus-diphtheria toxoid and acellular pertussis vaccine (Tdap). Pregnant women who travel or who have unavoidable exposures to vaccine-preventable diseases should be immunized. Breast-feeding is not a contraindication to the vaccination of mothers with inactivated and most live vaccines. Women who are not immune to rubella should be immunized after delivery. Similarly, the influenza and Tdap vaccinations may be administered postpartum in women who were not vaccinated during pregnancy. Copyright 2013, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23910028     DOI: 10.3928/00904481-20130723-09

Source DB:  PubMed          Journal:  Pediatr Ann        ISSN: 0090-4481            Impact factor:   1.132


  2 in total

1.  Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012.

Authors:  K Huygen; C Rodeghiero; D Govaerts; I Leroux-Roels; P Melin; M Reynders; S Van Der Meeren; S Van Den Wijngaert; D Pierard
Journal:  Epidemiol Infect       Date:  2013-09-27       Impact factor: 4.434

2.  Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data.

Authors:  Julie-Anne Quinn; Flor M Munoz; Bernard Gonik; Lourdes Frau; Clare Cutland; Tamala Mallett-Moore; Aimee Kissou; Frederick Wittke; Manoj Das; Tony Nunes; Savia Pye; Wendy Watson; Ana-Maria Alguacil Ramos; Jose F Cordero; Wan-Ting Huang; Sonali Kochhar; Jim Buttery
Journal:  Vaccine       Date:  2016-10-13       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.